The Influence of Aircraft Noise Exposure on Renal Hemodynamic in Healthy Individuals

NCT ID: NCT02783456

Last Updated: 2018-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological studies have found a link between aircraft noise exposure and increased incidence of arterial hypertension and thus cardiovascular disease. The underlying pathophysiological mechanisms are not yet fully understood. The kidney acts as a long-term regulator of blood pressure and controls the extracellular sodium and water balance. Significant renal mechanisms of blood pressure regulation are the renin angiotensin system, renal sympathetic activity and sodium excretion. Animal work and clinical studies show that mental stress affects the renal plasma flow and urinary sodium excretion. The investigators observed a lower sodium excretion in situations of mental stress in subjects at risk for developing arterial hypertension. In healthy volunteers, a 30-minute mental stress test resulted in increased glomerular filtration rate, filtration fraction and an increase in urinary sodium excretion. In this pilot study the investigators analyzed the influence of 30 minutes standardized aircraft noise on renal and central hemodynamics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The World Health Organisation (WHO) estimates that (about 340 million population) 1 million annually health life years are lost by environmental noise exposure in high-income countries of Western Europe. Aircraft noise is thereby assessed at comparable volume as unpleasant as road and rail noise. Epidemiological studies have found a link between aircraft noise exposure and increased incidence of arterial hypertension and thus cardiovascular disease. The underlying pathophysiological mechanisms are not yet fully understood.

The kidney acts as a long-term regulator of blood pressure and controls the extracellular sodium and water balance. Significant renal mechanisms of blood pressure regulation are the renin angiotensin system, renal sympathetic activity and sodium excretion. Animal work and clinical studies show that mental stress affects the renal plasma flow and urinary sodium excretion. In spontaneously hypertensive rats environmental stress resulted in sodium retention, triggered by increased renal sympathetic nerve activity, which is the development of arterial hypertension. In a pilot study in subjects at risk for developing arterial hypertension, the investigator observed a lower sodium excretion by mental stress. In healthy volunteers, a 30-minute mental stress test resulted in increased glomerular filtration rate, filtration fraction and an increase in urinary sodium excretion.

In the rabbit noise exposure leads to an increase of frequency and amplitude of discharges of renal sympathetic nerve activity and accompanied by a reduction of renal plasma flow. The impact of aircraft noise on renal plasma flow and urinary sodium excretion has, to our knowledge, so far not been studied in humans.

In this pilot study the Clinical Research Center investigate the influence of 30 minutes standardized aircraft noise on renal hemodynamics.

Hemodynamic renal changes should be considered in the context of the systemic circulation. Therefore, the central hemodynamics is determined in the present pilot study by bioimpedance cardiography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Individuals Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Noise and silence

Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.

Group Type ACTIVE_COMPARATOR

Noise

Intervention Type PROCEDURE

The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.

Silence

Intervention Type PROCEDURE

The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.

silence and noise

Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes

Group Type ACTIVE_COMPARATOR

Noise

Intervention Type PROCEDURE

The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.

Silence

Intervention Type PROCEDURE

The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Noise

The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.

Intervention Type PROCEDURE

Silence

The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with mild-moderate arterial hypertension (grade 1-2)
* Informed consent in writing available
* Willing and able to comply with all requirements of the study
* Male, between 18 and 50 years (inclusive)
* Body Mass Index (BMI) 18-27 kg/m2
* Non-smoker
* Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis).

Minor deviations of laboratory values, ECG, and vital sign parameters from the normal range may be accepted, if judged by the Investigator to have no clinical relevance.


\- uncomplicated arterial hypertension WHO grade 1-2, office blood pressure 140-179/90-109 mmHg

Exclusion Criteria

* Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgement).
* S-GOT or S-GPT levels \> 2-times above the upper limit of normal range.
* eGFR \< 60 ml/min/1,73m2 or kidney stones
* Clinically significant history of cardiovascular disease or any known present cardiovascular disease.
* History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders.
* Office blood pressure at screening higher than 140/100 mmHg
* Office heart rate at screening outside the range of 50-99 beats per minute (inclusive).
* Regular intake of medication within 1 month prior to study inclusion
* Participation in any other clinical study within 30 days prior to inclusion in this study.
* Clinically significant diseases (as judged by the investigator) within four weeks prior to screening
* History of alcohol or drug abuse.


* Regular intake of medication within 1 month prior to study inclusion
* office blood pressure at screening visit \> 180/110 mmHg
* secondary hypertension application of
* antihypertensive medication within 14 days prior to study inclusion
* of "other" medication
* Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgement).
* S-GOT or S-GPT levels \> 2-times above the upper limit of normal range.
* eGFR \< 60 ml/min/1,73m2 or kidney stones
* Clinically significant history of cardiovascular disease or any known present cardiovascular disease other than arterial hypertension.
* History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders, other than arterial hypertension.
* Office heart rate at screening outside the range of 50-99 beats per minute (inclusive).
* Regular intake of medication within 1 month prior to study inclusion
* Participation in any other clinical study within 30 days prior to inclusion in this study.
* Clinically significant diseases (as judged by the investigator) within four weeks prior to screening, other than arterial hypertension.
* History of alcohol or drug abuse.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland E. Schmieder, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Erlangen-Nürnberg Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Erlangen-Nuremberg

Erlangen, Bavaria, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

A. Jumar, C. Ott, J.M. Harazny, K. Striepe, M.V. Karg, R.E. Schmieder. NEW MODEL TO INVESTIGATE THE INFLUENCE OF AIRCRAFT NOISE IN THE PATHOPHYSIOLOGICAL CONCEPT OF HYPERTENSION J Hypertens 2017;35, e-Supplement 2:e214 PP.15.32

Reference Type RESULT

Bosch A, Rauh M, Striepe K, Schiffer M, Schmieder RE, Kannenkeril D. Renal adaptation in pre-obesity patients with hypertension. J Hypertens. 2024 Nov 1;42(11):1958-1965. doi: 10.1097/HJH.0000000000003821. Epub 2024 Jul 19.

Reference Type DERIVED
PMID: 39248112 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRCLÄRM2016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Handgrip Exercise Training and CKD
NCT07094906 RECRUITING NA
Hypertension in Hemodialysis
NCT00067665 COMPLETED NA